220 likes | 321 Views
Directorate of Laboratory Medicine. Dr Keith Hyde Clinical Director Pat Zukowskyj Directorate Manager. Corporate Brief. Agenda. CSB 3 Planning. CEO Review. Strategic Issues. Autolab. Agenda For Change - Vacancies. Human Resources. Finance. Finance. Trust Developments. Fire Lecture.
E N D
Directorate of Laboratory Medicine Dr Keith Hyde Clinical Director Pat Zukowskyj Directorate Manager Corporate Brief
Agenda CSB 3 Planning CEO Review Strategic Issues Autolab Agenda For Change - Vacancies Human Resources Finance Finance Trust Developments Fire Lecture
Clinical Director Dr. Keith Hyde
CSB III Planning • 4 floors – laboratory rectangle, core areas trapezium – many workshops! • Last Board meeting – rectangles presented • This Board meeting – core areas of 1st and 3rd floors presented • Next Board meeting – core areas of ground and 2nd floors hopefully presented!
CEO Review • Financial Problems • Savings Targets • DLM Pressures e.g. Histopathology • Triple Whammy - CRES/Vacancies - Activity (£) - Procurement Savings • National Targets - NSF’s, Cancer, Heart - Diagnosis to Treatment
Strategic Issues • City-Wide Immunology • HMDS (£1.0m) • Infection Control • Mortuary – External Review
Auto lab Review Key Messages • Accommodation • Productivity/Efficiency • Service Delivery • Resilience • Introduction IVF/ITU Service Turn-around Times Capacity
Directorate Manager Pat Zukowskyj
Agenda for Change 100%Submitted! KSF’s next
SICKNESS Sickness/absence % for DLM (in the 12 months ending April 2005)
Vacancy Update Summary of vacancies in the Directorate of Laboratory Medicine 2005/2006 (As at 03.06.2005)Total = 4
Finance Trust position = Annual Deficit £17m. To be addressed in 2 ways: • Try to get more from Commissioners (£5m) • £9.0m recurrent and £3m non-recurrent CRES Directorate share of this is: £216,905 recurrent, and £132,600 non-recurrent
News Trust developments which impact on DLM There have been recent developments for which there are financial implications for the DLM These are being pursued
Appointment of a Consultant ENTSurgeon with a special interest in Head & Neck Cancer Costs identified in January 2004, for a general ENT surgeon, were: £21.6K pay(of which £9.7K was for Histology) £10.5K(of which £3.9K was for Histology)
Appointment of an Oculoplastic Surgeon • New post, with 3 theatre sessions identified in the job plan • Initial bid to TMB put in with £10K for 0.1 wte consultant histopathologist, plus £15K for “pathology services” • Discussions resulted in an increase to 0.3 wte consultant histopathologist • We are now awaiting clarification of how the £15K for “pathology services” figure was created
Transfer of complex gynaecological cancer work from Tameside and Oldham to St Mary’s • Implication for Histology – consultant £45K, supporting staff £16.5K, nonpay £24.5K • Implication for other depts, totalling £42.1K
News “Pat ‘n’ Donuts” Lunch Time talk Sessions with Pat in the Laboratory Tea Rooms
Fire Lecture Malcolm Dunlop